MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Authorities in Wyoming say the search for Grant Gardner continue and have ramped up as the Lakeville native has not been ...

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company speeds up ...

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here.

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

MoonLake will be hosting an R&D Day for investors and analysts in San Diego, USA on Sunday, March 10 alongside the American Academy of Dermatology (AAD) annual meeting.

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11 th 2023. This session will be used to discuss the PsA market and ...

MoonLake To Tap Into Komodo’s Technology and Real-World Data To Unlock the Full Potential of Its Next-Gen Nanobody® Therapy April 10, 2024 07:00 AM Eastern Daylight Time ...

What happenedShares of the clinical-stage biotech MoonLake Immunotherapeutics (NASDAQ: MLTX) jumped by an eye-popping 78.8% over the first three and a half days of trading this week, according to ...

MoonLake also anticipates sharing an interim read out from the Phase 2 LEDA trial of sonelokimab in palmoplantar pustulosis (PPP), the first clinical trial in PPP for an IL-17A and IL-17F inhibitor.

MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments ...